No Data
Gan & Lee Pharmaceuticals (603087.SH): has repurchased a total of 0.2208% of its shares.
On March 3, Glenorchy reported that Gan & Lee Pharmaceuticals (603087.SH) announced that as of February 28, 2025, the company has repurchased a total of 1.327421 million shares, accounting for 0.2208% of the total equity, with a highest transaction price of 44.50 yuan/share and a lowest transaction price of 37.65 yuan/share, with a total amount of funds paid of approximately 55.112563 million yuan (excluding transaction fees).
Gan & Lee Pharma Doses First Subject for Insulin Drug's Phase III Trial; Shares Up 3%
Gan & Lee Pharmaceuticals (603087.SH): The first subject of the GZR4 insulin weekly formulation in China has completed drug administration in phase III clinical trials.
Gan & Lee Pharmaceuticals (603087.SH) announced that its independently developed GZR4 is currently conducting Phase III clinical trials in China...
Gan & Lee Pharmaceuticals Registers Diabetes Treatment Drug
Gan & Lee Pharmaceuticals (603087.SH): Subsidiary Englitazone tablets obtained pharmaceutical registration approval.
On February 10, Glodon announced that Gan & Lee Pharmaceuticals (603087.SH) has recently received the product registration approval for Empagliflozin tablets from the National Medical Products Administration. The acceptance number is CYHS2301895, and the pharmaceutical registration certificate number is 2025S00268. Empagliflozin is a high-selectivity sodium-glucose co-transporter 2 (SGLT2) inhibitor taken orally once daily. It reduces the kidneys' reabsorption of glucose by inhibiting SGLT2, promoting its excretion in urine, thus effectively lowering blood sugar levels. Empagliflozin has a unique ...
Gan & Lee Pharmaceuticals (603087.SH): has repurchased a total of 0.753621 million shares.
Gelonghui reported on February 5 that Gan & Lee Pharmaceuticals (603087.SH) announced that as of January 31, 2025, the company has repurchased a total of 0.753621 million shares, accounting for 0.1254% of the company's total share capital, with a highest transaction price of 44.13 yuan/share, a lowest transaction price of 37.65 yuan/share, and a total amount of funds paid of approximately 30.154816 million yuan (excluding transaction fees).
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
